Economics of Diabetes Mellitus

Nursing Clinics of North America

Volumn 41, Issue 4, 2006, Pages 499-511

  Krein, Sarah L ^a,b,c   Funnell, Martha M ^c   Piette, John D ^a,b,c  

^a VA ANN ARBOR HEALTHCARE SYSTEM   (United States)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

COST BENEFIT ANALYSIS; COST OF ILLNESS; DIABETES MELLITUS; DRUG COST; ECONOMICS; HEALTH CARE COST; HUMAN; INSURANCE; PATIENT COMPLIANCE; QUALITY ADJUSTED LIFE YEAR; REVIEW; UNITED STATES;

COST OF ILLNESS; COST-BENEFIT ANALYSIS; DIABETES MELLITUS; DRUG COSTS; HEALTH CARE COSTS; HUMANS; INSURANCE COVERAGE; PATIENT COMPLIANCE; QUALITY-ADJUSTED LIFE YEARS; UNITED STATES;

EID: 33751017078     PISSN: 00296465     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cnur.2006.07.003     Document Type: Review

References (52)

1. Engelgau M.M., Geiss L.S., Saaddine J.B., et al. The evolving diabetes burden in the United States. Ann Intern Med 140 (2004) 945-950
2. Centers for Disease Control and Prevention. National diabetes fact sheet: general information and national estimates on diabetes in the United States, 2005 (2005), US Department of Health and Human Services, Centers for Disease Control and Prevention, Atlanta (GA)
3. Honeycutt A.A., Boyle J.P., Broglio K.R., et al. A dynamic Markov model for forecasting diabetes prevalence in the United States through 2050. Health Care Manag Sci 6 (2003) 155-164
4. UK Prospective Diabetes Study Group (UKPDS). Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes (UKPDS 38). BMJ 317 (1998) 703-713
5. The Diabetes Control and Complications Trial Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 329 (1993) 977-986
6. UK Prospective Diabetes Study Group (UKPDS). Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 352 (1998) 837-853
7. Vijan S., Stevens D.L., Herman W.H., et al. Screening, prevention, counseling, and treatment for the complications of type II diabetes mellitus: putting evidence into practice. J Gen Intern Med 12 (1997) 567-580
8. The Early Treatment of Diabetic Retinopathy Study Research Group. Early photocoagulation for diabetic retinopathy. ETDRS Report Number 9. Ophthalmology 98 (1991) 766-785
9. Vijan S., and Hayward R.A. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med 138 (2003) 593-602
10. Vijan S., and Hayward R.A. Pharmacologic lipid-lowering therapy in type 2 diabetes mellitus: background paper for the American College of Physicians. Ann Intern Med 140 (2004) 650-658
11. Singh N., Armstrong D.G., and Lipsky B.A. Preventing foot ulcers in patients with diabetes. JAMA 293 (2005) 217-228
12. Anderson R.N., Minino A.M., Hoyert D.L., et al. Comparability of cause of death between ICD-9 and ICD-10: preliminary estimates. Natl Vital Stat Rep 49 (2001) 1-32
13. Snow V., Weiss K.B., and Mottur-Pilson C. The evidence base for tight blood pressure control in the management of type 2 diabetes mellitus. Ann Intern Med 138 (2003) 587-592
14. Druss B.G., Marcus S.C., Olfson M., et al. The most expensive medical conditions in America. Health Aff (Millwood) 21 (2002) 105-111
15. Hogan P., Dall T., and Nikolov P. Economic costs of diabetes in the US in 2002. Diabetes Care 26 (2003) 917-932
16. O'Brien J.A., Patrick A.R., and Caro J. Estimates of direct medical costs for microvascular and macrovascular complications resulting from type 2 diabetes mellitus in the United States in 2000. Clin Ther 25 (2003) 1017-1038
17. Caro J.J., Ward A.J., and O'Brien J.A. Lifetime costs of complications resulting from type 2 diabetes in the US. Diabetes Care 25 (2002) 476-481
18. Killilea T. Long-term consequences of type 2 diabetes mellitus: economic impact on society and managed care. Am J Manag Care 8 16 Suppl (2002) S441-S449
19. Economic and health costs of diabetes. Agency for Healthcare Research and Quality (AHRQ) HCUP Highlights. Pub. No. 04-0034 (2005), US Department of Health and Human Services, Agency for Healthcare Research and Quality, Rockville (MD)
20. Vijan S., Hayward R.A., and Langa K.M. The impact of diabetes on workforce participation: results from a national household sample. Health Serv Res 39 6 Pt 1 (2004) 1653-1669
21. Chapman L.S. Reducing obesity in work organizations. Am J Health Promot 19 (2004) 1-8 [discussion: 12]
22. Yancey A.K., McCarthy W.J., Taylor W.C., et al. The Los Angeles Lift Off: a sociocultural environmental change intervention to integrate physical activity into the workplace. Prev Med 38 (2004) 848-856
23. Katz D.L., O'Connell M., Yeh M.C., et al. Public health strategies for preventing and controlling overweight and obesity in school and worksite settings: a report on recommendations of the Task Force on Community Preventive Services. MMWR Recomm Rep 54 RR-10 (2005) 1-12
24. Gilmer T.P., O'Connor P.J., Rush W.A., et al. Predictors of health care costs in adults with diabetes. Diabetes Care 28 (2005) 59-64
25. Brandle M., Zhou H., Smith B.R., et al. The direct medical cost of type 2 diabetes. Diabetes Care 26 (2003) 2300-2304
26. Karter A.J., Stevens M.R., Herman W.H., et al. Out-of-pocket costs and diabetes preventive services: the Translating Research Into Action for Diabetes (TRIAD) study. Diabetes Care 26 (2003) 2294-2299
27. Piette J.D., Heisler M., and Wagner T.H. Problems paying out-of-pocket medication costs among older adults with diabetes. Diabetes Care 27 (2004) 384-391
28. Roblin D.W., Platt R., Goodman M.J., et al. Effect of increased cost-sharing on oral hypoglycemic use in five managed care organizations: how much is too much?. Med Care 43 (2005) 951-959
29. Soumerai S.B., Mah C., Zhang F., et al. Effects of health maintenance organization coverage of self-monitoring devices on diabetes self-care and glycemic control. Arch Intern Med 164 (2004) 645-652
30. Vijan S., Stuart N.S., Fitzgerald J.T., et al. Barriers to following dietary recommendations in type 2 diabetes. Diabet Med 22 (2005) 32-38
31. Heisler M., Langa K.M., Eby E.L., et al. The health effects of restricting prescription medication use because of cost. Med Care 42 (2004) 626-634
32. Piette J.D., Wagner T.H., Potter M.B., et al. Health insurance status, cost-related medication underuse, and outcomes among diabetes patients in three systems of care. Med Care 42 (2004) 102-109
33. Tamblyn R., Laprise R., Hanley J.A., et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 285 (2001) 421-429
34. Rosen A.B., Hamel M.B., Weinstein M.C., et al. Cost-effectiveness of full Medicare coverage of angiotensin-converting enzyme inhibitors for beneficiaries with diabetes. Ann Intern Med 143 (2005) 89-99
35. Fendrick A.M., Smith D.G., Chernew M.E., et al. A benefit-based copay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manag Care 7 (2001) 861-867
36. Piette J.D. Medication cost-sharing: helping chronically ill patients cope. Med Care 43 (2005) 947-950
37. Merin M. New Medicare benefits for people with diabetes. The new year brings new Medicare benefits and services for people with diabetes. Diabetes Forecast 58 (2005) 77
38. Bartol T. Coding and billing for patients with diabetes. Nurse Pract 30 (2005) 47-53
39. American Diabetes Association. Third-party reimbursement for diabetes care, self-management education, and supplies. Diabetes Care 29 Suppl 1 (2006) S68-S69
40. Guglielmo W.J. Does mandated diabetes coverage boost compliance?. Med Econ 78 (2001) 61-62 65
41. National Conference of State Legislatures. State Laws Mandating Diabetes Health coverage. Available at: www.ncsl.org/programs/health/diabetes.htm. Accessed January 27, 2006.
42. Hartsfield D., and Vinicor F. The role of law in health services delivery: diabetes and state-mandated benefits. J Law Med Ethics 31 4 Suppl (2003) 51
43. Conrad D.A., and Christianson J.B. Penetrating the black box: financial incentives for enhancing the quality of physician services. Med Care Res Rev 61 3 Suppl (2004) 37S-68S
44. Centers for Medicare and Medicaid Services. Medicare awards for programs to improve care of beneficiaries with chronic illnesses. Medicare Fact Sheet. Washington: Department of Health & Human Services, Centers for Medicare & Medicaid Services; 2004.
45. Norris S.L., Nichols P.J., Caspersen C.J., et al. The effectiveness of disease and case management for people with diabetes: a systematic review. Am J Prev Med 22 4 Suppl (2002) 15-38
46. In: Gold M.R., Siegel J.E., Russell L.B., et al. (Eds). Cost-effectiveness in health and medicine (1996), Oxford University Press, New York
47. CDC Diabetes Cost-effectiveness Group. Cost-effectiveness of intensive glycemic control, intensified hypertension control, and serum cholesterol level reduction for type 2 diabetes. JAMA 287 (2002) 2542-2551
48. Clarke P.M., Gray A.M., Briggs A., et al. Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Diabetologia 48 (2005) 868-877
49. Herman W.H., Hoerger T.J., Brandle M., et al. The cost-effectiveness of lifestyle modification or metformin in preventing type 2 diabetes in adults with impaired glucose tolerance. Ann Intern Med 142 (2005) 323-332
50. Eddy D.M., Schlessinger L., and Kahn R. Clinical outcomes and cost-effectiveness of strategies for managing people at high risk for diabetes. Ann Intern Med 143 (2005) 251-264
51. Knowler W.C., Barrett-Connor E., Fowler S.E., et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346 (2002) 393-403
52. Laupacis A., Feeny D., Detsky A.S., et al. How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations. CMAJ 146 (1992) 473-481